Aeglea BioTherapeutics aegleabio.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

Aeglea was founded in 2013 to develop engineered human enzymes. Aeglea's pipeline of engineered human enzymes includes AEB1102, which is expected to enter into clinical trials in both hyperargininemia and cancer. In addition, three additional drug candidates are in pre-clinical development: AEB4104, which degrades homocystine, is being evaluated as a potential treatment for the inborn error of metabolism homocystinuria; AEB3103, which degrades cysteine/cysteine, is being evaluated for its abilit...Show all

Aeglea was founded in 2013 to develop engineered human enzymes. Aeglea's pipeline of engineered human enzymes includes AEB1102, which is expected to enter into clinical trials in both hyperargininemia and cancer. In addition, three additional drug ca...Show all

Company (IPO / Went public)

Phone: 512-942-2935

Fax:

901 S. MoPac Expressway, Barton Oaks Plaza One
Suite 25
Austin, 78746
Texas, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Aeglea BioTherapeutics $56M Apr 7, 2016

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Aeglea BioTherapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 12 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)